DIALYSIS-TIR Study

NCT06042153 on ClinicalTrials.gov · last registry update 2026-01-13

Closed to new participants; the 43 already enrolled are still being followed. Due to report September 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Change in TIR (70-180 mg/dl). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 5 December 2023 — 2 years so far. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Texas Southwestern Medical Center
Sponsor type: Other
Enrollment: 43
Started: 2023-12-05
Primary completion: 2027-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in TIR (70-180 mg/dl)

Conditions studied

Type 2 Diabetes · End Stage Renal Disease on Dialysis

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.